The average percentage of tumor cells expressing cC3 was 32.2% (SD 16.3) for IgG, 43.5% (SD 9.3) for anti-PD-1, 49.1% (SD 12.5) for anti-IL-10, and 56.9% (SD 14.2) for anti-PD-1 and anti-IL-10 combination treatment. This evidence concerns the gene PDCD1 and neoplasm.